For example, if there are active immune activation signals between some tumor subpopulations and T cells (such CD80/CD28 or IFNG/IFNGR) (80), it could mean that the patient is more likely to respond to immunity therapy and could benefit from immune checkpoint inhibitors. The gene discussed is CD28; the disease is neoplasm.